-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 15, 2021, the State Administration of Market Supervision issued a notice stating that in accordance with Article 46 and Article 49 of the Anti-Monopoly Law, an administrative penalty decision was made, ordering Yangtze River Pharmaceutical Group to cease illegal activities and impose its 2018 A 3% fine of 25.
467 billion yuan in sales amounts to 764 million yuan.
It is reported that in November 2019, the State Administration for Market Regulation filed an investigation into Yangzijiang Pharmaceutical Group Co.
According to investigations, from 2015 to 2019, Yangtze River Pharmaceutical Group reached agreements with downstream companies such as drug wholesalers and retail pharmacies by signing cooperation agreements, issuing price adjustment letters, and oral notices across the country (excluding Hong Kong, Macao and Taiwan regions).
The General Administration of Market Supervision stated that drug prices are related to the national economy and people’s livelihood, and involve major issues such as reducing the burden of medical treatment and improving people’s livelihood.
